Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.
Dan Moldoveanu(McGill University Health Centre), Ian R. Watson(McGill University), Alexei Protopopov, Dana Vuzman, Béatrice Wang, M.G.V.M. Russel, Léon C.L.T. van Kempen(Vrije Universiteit Brussel), Kevin Petrecca(McGill University Health Centre), Sarkis Meterissian(McGill University), Mathieu Lajoie(McGill University Health Centre), Stephen Lyle(Beth Israel Deaconess Medical Center), Wilson H. Miller(Jewish General Hospital), Kevin Watters(McGill University Health Centre), Catalin Mihalcioiu(McGill University Health Centre), Matthew Dankner(McGill University), Sonia V. del Rincón(McGill University), Xiu Huang, Alan Spatz(Jewish General Hospital), Maria Lvova(Nickel Institute), Julie Y. Tse(Harvard University)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656